Status:
COMPLETED
TAXUS® Element™ Paclitaxel-Eluting Coronary Stent System European Post-Approval Surveillance Study (TE-Prove)
Lead Sponsor:
Boston Scientific Corporation
Collaborating Sponsors:
Pharmaceutical Research Associates
Conditions:
Coronary Heart Disease
Eligibility:
All Genders
Brief Summary
The goal of the TAXUS™ Element™ Paclitaxel-Eluting Coronary Stent System European Post-Approval Surveillance Study is to evaluate real world clinical outcomes data for the TAXUS™ Element™ Coronary Ste...
Detailed Description
A prospective, open label, multi-center observational study with an all-comers enrollment approach of approximately 1000 subjects at up to 50 sites in Europe.
Eligibility Criteria
Inclusion
- According to Instructions For Use
Exclusion
- Contraindications according to Instructions for Use
Key Trial Info
Start Date :
November 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 1 2015
Estimated Enrollment :
1014 Patients enrolled
Trial Details
Trial ID
NCT01242696
Start Date
November 1 2010
End Date
July 1 2015
Last Update
February 3 2017
Active Locations (37)
Enter a location and click search to find clinical trials sorted by distance.
1
Algemeen Ziekenhuis Sint-Jan
Bruges, Belgium, 8000
2
CHU de Charleroi - ISPPC
Charleroi, Belgium, 6000
3
H-Hartziekenhuis Roeselare-Menen vzw
Roeselare, Belgium, 8800
4
CH Avignon
Avignon, France, 84902